The BioMed X Institute
6.6.2024 14:57:41 CEST | ACCESS Newswire | Press release
A new research team at XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
RIDGEFIELD, CT / ACCESSWIRE / June 5, 2024 / XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut. This research team's main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel, in an effort to bridge the gap between research and development to improve patient outcomes accurately and efficiently.
The new research team is led by Dr. Lorenzo Talà, Group Leader at XSeed Labs. "Due to insufficient understanding of the mechanisms driving their pathology, therapies to treat fibrotic diseases are limited. The aim of our research group is to develop physiologically relevant in vitro and in silico fibrosis models. By combining both approaches, we will interrogate disease mechanisms, identify drug delivery pathways, and assess drug safety in order to facilitate drug development toward resolving fibrotic tissues."
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "We are pleased that we could successfully translate the innovation model we established in Heidelberg and New Haven to work inside a major pharma research and development campus. We have a long history of successful collaboration with Boehringer Ingelheim at our Heidelberg institute, and we are proud to extend this collaboration to their U.S. headquarters in Ridgefield, Connecticut."
"We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases," said Carine Boustany, PhD, U.S. Research Site Head and Global Head of Immunology and Respiratory Diseases Research, Boehringer Ingelheim. "In parallel, we will harness these innovative disease model systems to assess the safety of novel anti-fibrotic concepts, and identify better ways to deliver our molecules," said Xiaorong He, PhD, U.S. Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim.
"We are excited to start our first XSeed Labs team at Boehringer Ingelheim in Ridgefield. It is the beginning of a unique innovation model that promotes scientific exchange between major players in biomedical research," says Mark Johnston, CEO of BioMed X USA.
About BioMed X and XSeed Labs
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds -- academia and industry -- and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model - called XSeed Labs - entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27
Related Images
SOURCE: BioMed X Institute & XSeed Labs
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Assembly Hires Three Industry Leaders in Europe to Accelerate Growth27.2.2026 12:00:00 CET | Press release
Northway, Ayre, and Panchal add senior depth across AI and data strategy, programmatic activation, and client leadership as Assembly scales in Europe LONDON, UK / ACCESS Newswire / February 27, 2026 / Assembly enters 2026 with momentum and the leadership to match. The Stagwell media agency appoints James Northway as EVP, Global Head of AI and Data Strategy; David Ayre as Europe Head of Programmatic; and Bav Panchal as Europe Managing Partner, strengthening its bench across decision intelligence, activation, and client leadership. Assembly is building on its momentum in the region, following the recent Jabra win and the appointment of Bridget Hopkins as CEO of Europe. These strategic hires accelerate Assembly's expansion across Europe as clients push for integrated brand performance solutions that connect data, technology, media, and commerce to drive measurable growth. Assembly is meeting that demand through continued investment in its STAGE AI Experience Engine and Brand Performance P
Innodata Reports Fourth Quarter and Full Year 2025 Results26.2.2026 22:05:00 CET | Press release
48% Full-Year Revenue Growth and Strong Q4 Results Anticipates ~35%+ Revenue Growth in 2026 with Expanding Customer Diversification Announces Innovations in Dataset Creation and Evaluations for LLMs, AI Agents, and Physical AI (Robotics) NEW YORK CITY, NY / ACCESS Newswire / February 26, 2026 / INNODATA INC. (Nasdaq:INOD) today reported results for the fourth quarter and the year ended December 31, 2025. Revenue of $72.4 million for the three months ended December 31, 2025, representing 22% year-over-year organic revenue growth. Revenue of $251.7 million for the year ended December 31, 2025, representing 48% year-over-year organic revenue growth. Adjusted EBITDA of $15.7 million for the three months ended December 31, 2025, an increase of $1.6 million, or 11%, from $14.1 million in the same period last year.* Adjusted EBITDA of $57.9 million for the year ended December 31, 2025, an increase of $23.3 million, or 68%, from $34.6 million in the same period last year.* Net income of $8.8 m
Loar Holdings Inc. Reports Q4 2025 and Full Year 2025 Record Results, and Upward Revisions to Full Year 2026 Outlook26.2.2026 14:30:00 CET | Press release
WHITE PLAINS, NY / ACCESS Newswire / February 26, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reports record results for the fourth quarter and full year of 2025 and upward revisions to the full year 2026 outlook. "As we close the year, I am pleased to report that Loar once again delivered record results across key financial metrics, including Net Sales, Adjusted EBITDA, and Adjusted EBITDA Margin," said Dirkson Charles, Loar CEO and Executive Co‑Chairman of the Board of Directors. "Driven by favorable end‑market dynamics and disciplined execution across the organization, our team delivered strong operating performance while advancing our long‑term value creation strategy. These results underscore the scalability and resilience of our business model and reinforce Loar's position as a leading aerospace and defense component supplier. We also successfully completed the acquisitions of LMB Fans & Motors and Harper Engineering, further strengthening
U.S. Polo Assn. Returns as Official Apparel and Jersey Sponsor of the 2026 Dubai Polo Gold Cup for Third Consecutive Year26.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL AND DUBAI, UAE / ACCESS Newswire / February 26, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly served as the Official Apparel and Jersey Sponsor of the 2026 Dubai Polo Gold Cup, held January 28 through February 14 at the renowned Al Habtoor Polo Club in Dubai, United Arab Emirates.Dubai Wolves by Thera with their trophy on stage at the Dubai Polo Gold Cup 2026 at the Al Habtoor Polo Club Photo Credit: Margarita Crotto Now marking its third consecutive year supporting the prestigious tournament, U.S. Polo Assn. provided custom performance jerseys to participating teams, apparel for event staff, and exclusive player prizes for the finalists. Spectators joined in the excitement during the traditional divot stomp with a special U.S. Polo Assn. cap giveaway, adding a spirited fan moment to the two-week competition in the UAE. The 2026 Dubai Polo Gold Cup Final delivered an electrifying showdown of world-renowned pl
Innovation Holds Key to Future Growth, New Research from Ipsos, Alchemy-RX and Market Logic Finds26.2.2026 10:00:00 CET | Press release
Global organisations are doubling down on innovation and consumer understanding, as they look to grow revenues in the next three years. LONDON, UK / ACCESS Newswire / February 26, 2026 / A new study, Innovation Reignited: C-Suite insights on the state of innovation, from Ipsos, Alchemy-RX and Market Logic reveals that innovation is rapidly becoming the cornerstone of corporate growth strategies worldwide. According to the findings of the survey of C-Suite executives, 82% of companies expect innovation to drive growth strategy. Still, only the most ambitious leaders (33%) anticipate this will account for more than 20% of revenue in the next three years. However, with respondents reporting that less than 75% of innovation launches meet all their launch goals, the risk of missing ambitious growth targets is significant for those who do not optimise their innovation processes. Deeper customer understanding is key While the need to adopt a customer-centric approach to every stage of innovat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom